Filing Flows › Neuronetics (STIM) › Guidance & outlook
Neuronetics (STIM) guidance and outlook
Neuronetics (STIM) raised some and lowered other parts of its guidance on Nov 4, 2026: Revenue $160M–$164M for FY2026; Gross margin 49%–50% for FY2026; Stock-based compensation $3.5M for FY2026; Operating expenses $92.5M–$95.5M for FY2026. Neuronetics' 10-Q filed Nov 4, 2026 makes 14 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $160M–$164M | reaffirmed |
| Gross margin | FY2026 | 49%–50% | raised |
| Stock-based compensation | FY2026 | $89.0M–$92.0M | new |
| Stock-based compensation | FY2026 | $3.5M | lowered |
| Operating expenses | FY2026 | $92.5M–$95.5M | lowered |
| Stock-based compensation | FY2026 | $1.0M | new |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Our sales force targets an estimated 53,000 psychiatrists across 26,000 practices.
- We expect to continue to expand our direct sales and customer support team to further penetrate the market by demonstrating the benefits of the System to providers and their patients.
- Net patient fees are estimated using an expected value approach where management considers such variables as the average of previous net patient fees received by the applicable payor and fees received by other patients for similar services and the Company’s best estimate leveraging industry knowledge and expectations of third-party payors’ fee schedules.
- We expect Greenbrook revenue to increase in 2026.
- We expect our cost of revenues to increase, primarily driven by changes in the overall business mix, as well as growth in volume.
- Our gross margin has been and will continue to be affected by a variety of factors, primarily product sales mix, pricing and third-party contract manufacturing costs.
- We anticipate that our sales and marketing expenses will decrease in 2026 relative to 2025 as a result of the cost efficiencies realized post-acquisition across the sales and marketing divisions.
- We anticipate that our general and administrative expenses will decrease during 2026 compared to 2025 expenses.
- We expect our research and development expenses to decrease during 2026 compared to 2025 expenses.
- The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales and marketing and product development activities.
- We cannot be assured that additional equity, equity-linked or debt financing will be available on terms favorable to us or our stockholders, or at all.
- It is also possible that we may allocate significant amounts of capital towards products or technologies for which market demand is lower than expected and, as a result, abandon such efforts.
Neuronetics' latest quarter
Neuronetics, Q3 2026: revenue $42.0M (+12% year over year), operating margin 1.3%, net loss $1.6M, operating cash flow $1.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Neuronetics raise or lower its guidance?
Neuronetics (STIM) raised some and lowered other parts of its guidance on Nov 4, 2026: Revenue $160M–$164M for FY2026; Gross margin 49%–50% for FY2026; Stock-based compensation $3.5M for FY2026; Operating expenses $92.5M–$95.5M for FY2026.
What does Neuronetics expect?
Our sales force targets an estimated 53,000 psychiatrists across 26,000 practices. We expect to continue to expand our direct sales and customer support team to further penetrate the market by demonstrating the benefits of the System to providers and their patients. Net patient fees are estimated using an expected value approach where management considers such variables as the average of previous net patient fees received by the applicable payor and fees received by other patients for similar services and the Company’s best estimate leveraging industry knowledge and expectations of third-party
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.